Avoiding Drug-Drug Interactions

Åstrand, Bengt

doi:10.1159/000218100

Cited by 17 publications

(10 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, other studies are necessary to analyze methotrexate concentration at a given time point but also the area under the curve of methotrexate with and without PPI, in order to not simply categorize outcomes as delayed elimination or not delayed. To avoid such potential drug-drug interactions, reliable information about drugs needs to be available in databases accessible to all health professionals [28]. Prescribers and pharmacists have to know the individual’s current drug therapy, especially if PPI or methotrexate is taken by the patient.…”

Section: Discussionmentioning

confidence: 99%

Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?

Ranchon¹,

Vantard²,

Gouraud

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma. Valaciclovir, fluoxetine and pantoprazole were given concomitantly. A methotrexate overdosage was shown at 36 h after infusion associated with a severe renal failure. Alkaline hyperhydration, folinic acid and carboxypeptidase G2 were given. Prescription analyses by pharmacists and literature research have permitted us to suggest that a drug-drug interaction between methotrexate and proton pump inhibitors (PPI) was responsible for this renal failure. Several mechanisms of interaction were suggested and might be related to the inhibition of renal methotrexate transporters by PPI, an increase in the methotrexate efflux to the blood by an upregulation of multidrug resistance protein 3 by PPI or genetic polymorphisms. This case shows that pharmacists can help physicians to optimize patient treatment: they consensually decided on the systematic discontinuation of PPI or a switch to ranitidine when patients were treated by high-dose methotrexate.

show abstract

Section: Discussionmentioning

confidence: 99%

Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?

Ranchon¹,

Vantard²,

Gouraud

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…It should be mentioned that irrational combinations do not necessarily involve drug-drug interactions; therefore this paper will touch upon potential interactions. According to B.Astrand, 17% to 23% of drug combinations are associated with such a risk, and only from 6% to 8% of them actually result in an interaction (Astrand 2009). However, a number of factors, such as a narrow therapeutic index of many psychoactive drugs (Spina et al 2016, Hiemke et al 2018, predominantly hepatic metabolism involving the cytochrome P450 system (Guo et al 2012, de Leon andSpina 2018), and antipsychotic polytherapy (use of several antipsychotic drugs) (Tranulis et al 2008, Correll et al 2009, Misawa et al 2011, can increase the occurrence of drugdrug interactions in the treatment of psychiatric inpatients.…”

Section: Introductionmentioning

confidence: 99%

Potential drug-drug interactions in the psychiatric hospital: Frequency analysis

Kirilochev¹,

Дорфман²,

Умерова³

et al. 2019

RRP

View full text Add to dashboard Cite

Citation: Kirilochev OO, Dorfman IP, Umerova AR, Bataeva SE (2019) Potential drug-drug interactions in the psychiatric hospital: Frequency analysis. Research Results in Pharmacology 5(4): 1-6. https://doi. AbstractIntroduction: Drug-drug interactions are an important clinical problem in pharmacotherapy. This study is focused on different types of drugs used in a psychiatric hospital. Materials and methods:The pharmacoepidemiological study included the analysis of medical records of 500 psychiatric inpatients. The patients were divided into 2 groups: under 65 and over 65 years of age. All the drug prescriptions were analyzed to identify the combinations of drugs that can induce drug-drug interactions and determine their clinical significance.Results and discussion: Over 77% of hospitalized patients were administered drug combinations that could induce drug-drug interactions, most of which were of moderate clinical significance. A reliable association was found between the patient's age, the clinical significance of drug-drug interactions, and the pharmacotherapy structure. The most common irrational drug combinations were identified.Conclusion: Timely analysis of drug prescriptions for potential drug-drug interactions can enhance the safety of pharmacotherapy and decrease the risk of adverse drug reactions in the psychiatric inpatient setting. Keywordsadverse drug reactions, drug-drug interactions, pharmacotherapy safety. Copyright Kirilochev OO et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Research Results in Pharmacology 5(4): 1-6 UDC: 615.065

show abstract

“…The extensive distribution and diverse physiologic functions of Pgp leads us to consider that this protein may have an important role in the process of absorption, distribution and elimination of several drugs. Because the participation of Pgp and estrogenic hormones in drug-drug interactions has not been widely studied, further investigations need to be done to prevent the decrease in therapeutic effect or adverse reactions [28] .…”

Section: Discussionmentioning

confidence: 99%

Effects of 17β-Estradiol on the Cytotoxicity of Etoposide in a Lung Carcinoma Cell Line and Its Bioavailability in Ovariectomized Sprague-Dawley Rats

Guerrero‐Vargas¹,

Jurado²,

Virto-Aguilar³

et al. 2010

Chemotherapy

View full text Add to dashboard Cite

Background: The activity of steroid hormones for the efficacy of antineoplastic drugs used in lung cancer treatment has not been explored. We evaluated the influence of 17β-estradiol on the cytotoxicity of etoposide in a lung cancer cell line (A-549) and determined systemic levels of etoposide in vivoafter pretreatment with this hormone. Methods: The effect of 17β-estradiol alone and combined with etoposide on cellular proliferation was evaluated. Blood levels of etoposide were studied in ovariectomized female rats previously treated with 17β-estradiol. Etoposide levels were determined by high-performance liquid chromatography, and a pharmacokinetic analysis was performed. Results: 17β-Estradiol showed a tendency towards an increase in cellular proliferation but did not change the cytotoxic effect of etoposide. This in vivo study demonstrated that the blood levels of etoposide significantly decreased in the 17β-estradiol-treated group. Conclusion: The clear reduction in the in vivo systemic levels of etoposide in the presence of 17β-estradiol suggests a possible role of this hormone in drug resistance. However, as these data cannot be extrapolated to clinic situations, more research is necessary to understand the interaction between hormonal compounds and antineoplastic drugs.

show abstract

Avoiding Drug-Drug Interactions

Cited by 17 publications

References 85 publications

Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?

Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?

Potential drug-drug interactions in the psychiatric hospital: Frequency analysis

Effects of 17β-Estradiol on the Cytotoxicity of Etoposide in a Lung Carcinoma Cell Line and Its Bioavailability in Ovariectomized Sprague-Dawley Rats

Contact Info

Product

Resources

About